IL104479A - History of quinazoline, the processes for their preparation and pharmacy preparations containing them and their use - Google Patents

History of quinazoline, the processes for their preparation and pharmacy preparations containing them and their use

Info

Publication number
IL104479A
IL104479A IL10447993A IL10447993A IL104479A IL 104479 A IL104479 A IL 104479A IL 10447993 A IL10447993 A IL 10447993A IL 10447993 A IL10447993 A IL 10447993A IL 104479 A IL104479 A IL 104479A
Authority
IL
Israel
Prior art keywords
quinazoline
mixture
formula
alkyl
alkoxy
Prior art date
Application number
IL10447993A
Other languages
English (en)
Hebrew (he)
Other versions
IL104479A0 (en
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929201095A external-priority patent/GB9201095D0/en
Priority claimed from GB929213572A external-priority patent/GB9213572D0/en
Priority claimed from GB929223735A external-priority patent/GB9223735D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL104479A0 publication Critical patent/IL104479A0/xx
Publication of IL104479A publication Critical patent/IL104479A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Cosmetics (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL10447993A 1992-01-20 1993-01-21 History of quinazoline, the processes for their preparation and pharmacy preparations containing them and their use IL104479A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929201095A GB9201095D0 (en) 1992-01-20 1992-01-20 Quinazoline derivatives
GB929213572A GB9213572D0 (en) 1992-06-26 1992-06-26 Quinazoline derivatives
GB929223735A GB9223735D0 (en) 1992-11-12 1992-11-12 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
IL104479A0 IL104479A0 (en) 1993-05-13
IL104479A true IL104479A (en) 1999-12-22

Family

ID=27266013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10447993A IL104479A (en) 1992-01-20 1993-01-21 History of quinazoline, the processes for their preparation and pharmacy preparations containing them and their use

Country Status (22)

Country Link
US (2) US5457105A (de)
EP (1) EP0566226B1 (de)
KR (1) KR100229294B1 (de)
AT (1) ATE130000T1 (de)
AU (1) AU661533B2 (de)
CA (1) CA2086968C (de)
CZ (1) CZ282038B6 (de)
DE (1) DE69300754T2 (de)
DK (1) DK0566226T3 (de)
ES (1) ES2078798T3 (de)
FI (1) FI111631B (de)
GB (1) GB9300059D0 (de)
GR (1) GR3018143T3 (de)
HK (1) HK36497A (de)
HU (2) HU221622B1 (de)
IL (1) IL104479A (de)
NO (1) NO301541B1 (de)
NZ (1) NZ245662A (de)
RU (1) RU2127263C1 (de)
SK (1) SK281551B6 (de)
TW (1) TW283146B (de)
UA (1) UA34426C2 (de)

Families Citing this family (677)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
AU739382B2 (en) * 1993-12-10 2001-10-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5736534A (en) * 1994-02-23 1998-04-07 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
AU778961B2 (en) * 1995-03-30 2004-12-23 Osi Pharmaceuticals, Inc. Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives
NZ304859A (en) * 1995-04-03 2000-01-28 Novartis Ag 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ZA9756B (en) * 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
YU5399A (sh) * 1996-08-06 2002-03-18 Pfizer Inc. Supstituisani pirido-ili pirimido-derivati koji sadrže 6,6- ili 6,7-biciklične prstenove
AU4342997A (en) * 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (de) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
JP2000505109A (ja) * 1996-11-27 2000-04-25 ファイザー・インク 縮合二環式ピリミジン誘導体
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
BR9812122A (pt) * 1997-08-15 2000-07-18 Cephlon Inc Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
IL135109A0 (en) 1997-09-26 2001-05-20 Asta Medica Ag Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
AU2237899A (en) 1998-01-21 1999-08-09 Sugen, Inc. Human orthologues of wart
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
EP1073723B1 (de) 1998-04-14 2005-08-17 Sugen, Inc. Ste20-verwandte proteinkinasen
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000012084A1 (en) 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
JP4537582B2 (ja) 1998-09-29 2010-09-01 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
NZ510210A (en) 1998-10-01 2003-06-30 Astrazeneca Ab 4-phenylamino substituted quinazoline or quinoline derivatives useful for treating cytokine mediated diseases or conditions
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP4619545B2 (ja) 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
RS49836B (sr) * 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
WO2000069459A1 (en) 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
AU775285B2 (en) * 1999-06-21 2004-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
DE60037020T2 (de) 1999-07-09 2008-08-21 Glaxo Group Ltd., Greenford Anilinochinazoline als protein-tyrosin-kinasehemmer
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3832002A3 (en) * 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
JP4870304B2 (ja) * 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
EP1229025A4 (de) * 1999-10-01 2003-04-09 Japan Energy Corp Neue quinazolinderivate
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
EP1254123A1 (de) 2000-02-07 2002-11-06 Abbott GmbH & Co. KG 2-benzothiazolylharnstoff-derivate und ihre verwendung als proteinkinase inhibitoren
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2001239770B2 (en) 2000-02-15 2006-01-05 Pharmacia & Upjohn Company Pyrrole substituted 2-indolinone protein kinase inhibitors
SI1274692T1 (sl) * 2000-04-07 2006-12-31 Astrazeneca Ab Kinazolinske spojine
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
KR20080027400A (ko) 2000-08-21 2008-03-26 아스트라제네카 아베 퀴나졸린 유도체
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
NZ527692A (en) 2001-02-19 2005-05-27 Novartis Ag Cancer treatment
CA2439143A1 (en) * 2001-02-26 2002-09-06 Mcgill University Combi-molecules having signal transduction inhibitory properties and dna damaging properties
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2002079498A1 (en) * 2001-04-02 2002-10-10 Merck & Co., Inc. In vivo methods of determining activity of receptor-type kinase inhibitors
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2163256B1 (de) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Spezifische Bindeproteine und deren Verwendungen
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
WO2002092577A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
MXPA03010401A (es) 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
KR100397792B1 (ko) 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
MXPA04003385A (es) 2001-10-10 2005-04-11 Sugen Inc Derivados de 3-?4-substituido con heterociclilo)-pirrol-2-ilmetilidene?-2-indolinona como inhibidores de cinasa.
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR20040085151A (ko) * 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
US7612077B2 (en) * 2002-02-26 2009-11-03 Astrazeneca Ab Crystalline forms of the anti-cancer compound ZD1839
GB0204392D0 (en) * 2002-02-26 2002-04-10 Astrazeneca Ab Pharmaceutical compound
AU2003208444B2 (en) * 2002-02-26 2006-10-26 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ES2280735T3 (es) * 2002-04-16 2007-09-16 Astrazeneca Ab Terapia de combinacion para el tratamiento de cancer.
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
CA2486270C (en) 2002-06-05 2015-07-28 Genentech, Inc. Vegfr modulating agents and methods for liver growth and liver protection
GB0221245D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US20040156869A1 (en) * 2002-12-13 2004-08-12 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
CN1972712A (zh) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
JP2006527235A (ja) 2003-06-10 2006-11-30 エフ．ホフマン−ラ　ロシュ　アーゲー １，３，４−トリアザフェナレンおよび１，３，４，６−テトラアザフェナレン誘導体
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
KR20060054388A (ko) * 2003-07-29 2006-05-22 아스트라제네카 아베 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체
DE602004010284T2 (de) 2003-07-31 2008-10-02 Sanofi-Aventis Aminochinolinderivate und deren verwendung als adenosin-a3-liganden
JP2007501229A (ja) 2003-08-06 2007-01-25 スゲン，インコーポレイティド 強力なプロテインキナーゼ阻害剤としての幾何学的に束縛された３−シクロペンチリデン−１，３−ジヒドロインドール−２−オン類
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
US20080234263A1 (en) * 2003-09-16 2008-09-25 Laurent Francois Andre Hennequin Quinazoline Derivatives
PT1667991E (pt) 2003-09-16 2008-07-14 Astrazeneca Ab Derivados de quinazolina como inibidores da tirosina cinase
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
DK1667992T3 (da) * 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
US20070043010A1 (en) * 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
WO2005048928A2 (en) * 2003-11-12 2005-06-02 George Mason Intellectual Property Methods for treating viral infection
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
CA2552658A1 (en) * 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
AU2005214373B2 (en) * 2004-02-19 2011-07-28 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
CN103007279B (zh) * 2004-03-19 2017-01-11 英克隆有限责任公司 人抗表皮生长因子受体抗体
EP2447375B1 (de) 2004-03-31 2019-05-08 The General Hospital Corporation Verfahren zur Bestimmung des Ansprechens von Krebs auf den epidermalen Wachstumsfaktorrezeptor gerichtete Behandlungen
CA2560162C (en) 2004-04-07 2013-05-21 Novartis Ag Inhibitors of iap
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
EP1773881A4 (de) * 2004-05-13 2008-08-06 Imclone Systems Inc Hemmmung des makrophagen-stimulierenden proteinrezeptors (ron)
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
JP4881875B2 (ja) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
RU2414457C2 (ru) 2005-02-23 2011-03-20 Сионоги Энд Ко., Лтд. Производные хиназолина, обладающие ингибирующей активностью в отношении тирозинкиназы
UY29398A1 (es) 2005-02-26 2006-10-02 Astrazeneca Ab Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións.
US7358256B2 (en) * 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
US8309133B2 (en) * 2005-04-12 2012-11-13 Alkermes Pharma Ireland Limited Nanoparticulate quinazoline derivative formulations
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080019249A (ko) 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
EP1909819A4 (de) 2005-06-17 2010-02-17 Imclone Llc Rezeptor-antagonisten zur behandlung von metastatischem knochenkrebs
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP1957468A2 (de) 2005-09-06 2008-08-20 T.K. Signal Ltd. Polyalkylenglykolderivate von 4-(phenylamino)chinazolinen, die sich als irreversible inhibitoren der tyrosinkinase des rezeptors für den epidermalen wachstumsfaktor eignen
ES2354457T3 (es) 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
BRPI0620462A2 (pt) * 2005-12-22 2011-11-16 Astrazeneca Ab composto, processo para preparar um composto, composição farmacêutica, uso de um composto, e,métodos para produzir um efeito inibidor de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
EP2004163B1 (de) 2006-04-05 2014-09-17 Novartis Pharma AG Kombination von everolimus und vinorelbin
WO2007115289A2 (en) 2006-04-05 2007-10-11 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
KR20080110912A (ko) 2006-04-19 2008-12-19 노파르티스 아게 인다졸 화합물 및 ｃｄｃ７의 억제 방법
EP2026800A1 (de) 2006-05-09 2009-02-25 Novartis AG Kombination aus einem eisenchelatbildner und einem anti-neoplastischen mittel und ihre verwendung
CN101490046A (zh) 2006-05-09 2009-07-22 辉瑞产品公司 环烷基氨基酸衍生物及其药物组合物
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033748A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
EP2061772A4 (de) * 2006-09-11 2011-06-29 Curis Inc Multifunktionale kleine moleküle als proliferationshemmende wirkstoffe
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
PT2068880E (pt) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Método para tratamento do cancro apresentando mutações no egfr
JP2010504974A (ja) * 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8586621B2 (en) 2006-10-27 2013-11-19 Michael A. Zeligs Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CN101245050A (zh) 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐
PE20090519A1 (es) 2007-02-15 2009-05-29 Novartis Ag Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
NZ580671A (en) 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
GEP20125581B (en) 2007-04-18 2012-07-25 Pfizer Prod Inc Sulfonyl amide derivatives for treatment of abnormal cell growth
JP2010527951A (ja) * 2007-05-24 2010-08-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
MX2010001757A (es) * 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2008299896B2 (en) * 2007-09-10 2012-02-02 Curis, Inc. Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
KR20100099128A (ko) * 2007-10-19 2010-09-10 파르마 마르 에스.에이. 개선된 항암치료
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
UA101168C2 (ru) * 2007-10-29 2013-03-11 Натко Фарма Лимитед 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства
SG185942A1 (en) 2007-11-02 2012-12-28 Agency Science Tech & Res Methods and compounds for preventing and treating a tumour
EP2060565A1 (de) 2007-11-16 2009-05-20 4Sc Ag Neue bifunktionelle Verbindungen die Proteinkinasen und Histonedeacetylasen hemmen
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
WO2009067242A2 (en) * 2007-11-20 2009-05-28 Imclone Llc Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
AR069393A1 (es) * 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
EP2072502A1 (de) * 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
EA018514B1 (ru) 2008-01-18 2013-08-30 Натко Фарма Лимитед 6,7-диалкокси хиназолиновые производные, эффективные для лечения нарушений, связанных с раком
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP2011515330A (ja) * 2008-01-30 2011-05-19 ファルマ・マール・ソシエダード・アノニマ 改良抗腫瘍治療剤
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
DE102008009609A1 (de) 2008-02-18 2009-08-20 Freie Universität Berlin Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
CN101959533A (zh) * 2008-03-05 2011-01-26 诺瓦提斯公司 嘧啶衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的物质具有获得性耐药性的疾病中的用途
RU2010140890A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
JP5637982B2 (ja) * 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CA2723989C (en) 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
WO2010015522A1 (de) 2008-08-08 2010-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2344161B1 (de) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Kombinationen eines liposomalen wasserlöslichen camptothecins mit cetuximab oder bevacizumab
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
ES2478842T3 (es) 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
WO2010080409A1 (en) 2008-12-18 2010-07-15 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
EP2400990A2 (de) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
EP2473500A2 (de) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazolderivate
DK3575288T3 (da) 2009-09-03 2021-12-20 Bristol Myers Squibb Co Quinazoliner som kaliumionkanalinhibitorer
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP2491032B1 (de) 2009-10-23 2014-04-16 Eli Lilly and Company Akt-hemmer
EP2494070A2 (de) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Verfahren zur krebsbehandlung bei patienten mit igf-1r-hemmer-resistenz
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
AR078986A1 (es) 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
EA201200617A1 (ru) 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
CN102648188A (zh) 2009-12-08 2012-08-22 诺瓦提斯公司 杂环磺酰胺衍生物
AU2012265844A1 (en) 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
WO2011086053A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
EA201201289A1 (ru) 2010-03-16 2013-08-30 Мерк Патент Гмбх Морфолинилхиназолины
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
EP2558864A1 (de) 2010-04-16 2013-02-20 Genentech, Inc. Fox03a als prädiktiver biomarker zur hemmung des pi3k/akt-kinasesignalweges
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP5802756B2 (ja) 2010-10-20 2015-11-04 ファイザー・インク スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
EP2640722B1 (de) 2010-11-19 2015-11-04 F.Hoffmann-La Roche Ag Pyrazolpyridine sowie ihre verwendung als tyk2 inhibitoren
CN103270026A (zh) 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
EP2468883A1 (de) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2492688A1 (de) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
MX341456B (es) 2011-03-04 2016-08-18 Glaxosmithkline Ip Dev Ltd Amino-quinolinas como inhibidores de cinasa.
SG193291A1 (en) 2011-03-04 2013-10-30 Newgen Therapeutics Inc Alkyne substituted quinazoline compound and methods of use
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
WO2012125913A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201106870D0 (en) 2011-04-26 2011-06-01 Univ Belfast Marker
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
CN103608349A (zh) 2011-06-27 2014-02-26 诺瓦提斯公司 四氢-吡啶并-嘧啶衍生物的固体形式和盐
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
MX2014001595A (es) 2011-08-12 2014-04-14 Hoffmann La Roche Compuestos de imidazol, composiciones y metodos de uso.
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
CN104024432B (zh) 2011-08-31 2017-02-22 基因泰克公司 诊断性标志物
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
CA2845409A1 (en) 2011-09-20 2013-03-28 Yingjie Lai Imidazopyridine compounds, compositions and methods of use
ES2575710T3 (es) 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
CN104066851A (zh) 2011-09-30 2014-09-24 基因泰克公司 肿瘤或肿瘤细胞中上皮或间充质表型的诊断性甲基化标志物和对egfr激酶抑制剂的响应
EP2766497A1 (de) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Verfahren zur auswahl und behandlung von krebs bei patienten mit igf-1r/ir-hemmern
AP2014007601A0 (en) 2011-10-28 2014-04-30 Novartis Ag Novel purine derivatives and their use in the treatment of disease
EP2785717B1 (de) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidinverbindungen
EP2785864A2 (de) 2011-11-30 2014-10-08 F. Hoffmann-La Roche AG Erbb3-mutationen bei krebs
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103172641B (zh) 2011-12-20 2014-06-11 钱卫 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
KR101656592B1 (ko) 2011-12-22 2016-09-23 노파르티스 아게 디히드로-벤조-옥사진 및 디히드로-피리도-옥사진 유도체
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
JP2015503519A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
CN104136428A (zh) 2011-12-23 2014-11-05 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US9193718B2 (en) 2012-03-26 2015-11-24 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Quinazoline derivative and application thereof
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103373966A (zh) * 2012-04-17 2013-10-30 南京大学 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途
NZ700924A (en) 2012-05-16 2016-02-26 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP2855483B1 (de) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinonverbindungen
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
CA2888803A1 (en) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
CA3102531A1 (en) 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
BR112015019603A2 (pt) 2013-02-20 2017-08-22 Novartis Ag Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
ES2654100T3 (es) 2013-02-21 2018-02-12 Glaxosmithkline Intellectual Property Development Limited Quinazolinas como inhibidores de quinasa
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
RS56566B1 (sr) 2013-03-06 2018-02-28 Astrazeneca Ab Inhibitori hinazolina aktivirajućih mutantnih oblika receptora epidermalnog faktora rasta
BR112015022545A2 (pt) 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
SG11201507477XA (en) 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
EP2968565A2 (de) 2013-03-14 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
EP2968537A1 (de) 2013-03-15 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014147631A1 (en) 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
CN105102450B (zh) 2013-04-04 2018-03-09 詹森药业有限公司 作为PERK抑制剂的N‑(2，3‑二氢‑1H‑吡咯并[2，3‑b]吡啶‑5‑基)‑4‑喹唑啉胺和N‑(2，3‑二氢‑1H‑吲哚‑5‑基)‑4‑喹唑啉胺衍生物
CN103275019B (zh) * 2013-04-26 2016-05-18 浙江工业大学 4-[3-氯-4-取代苯胺基]-6-取代甲氧基甲酰氨基喹唑啉类化合物及制备和应用
CN103382182B (zh) * 2013-05-17 2016-08-10 河北医科大学 苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103304491A (zh) * 2013-06-17 2013-09-18 连云港盛和生物科技有限公司 一种吉非替尼的制备方法
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
MY184292A (en) 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
CN103483276B (zh) * 2013-09-22 2018-04-17 南京恒道医药科技有限公司 一种凡德他尼杂质的制备方法
WO2015049325A1 (en) 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
SG11201604979WA (en) 2013-12-17 2016-07-28 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3327006B1 (de) 2014-03-28 2020-05-20 Calitor Sciences, LLC Substituierte heteroarylverbindungen und verfahren zur verwendung
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
AP2016009530A0 (en) 2014-04-30 2016-10-31 Pfizer Cycloalkyl-linked diheterocycle derivatives
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
EP3189046B1 (de) 2014-09-05 2020-08-26 Genentech, Inc. Therapeutische verbindungen und ihre verwendung
EP3193866A1 (de) 2014-09-19 2017-07-26 Genentech, Inc. Verwendung von cbp/ep300- und bet-inhibitoren zur behandlung von krebs
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3632915A1 (de) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1-h-pyrazolo[4,3-c]pyridin-3-amin-verbindungen als cbp- und/oder ep300-inhibitoren
WO2016106340A2 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
EP3237638B1 (de) 2014-12-24 2020-01-15 F.Hoffmann-La Roche Ag Therapeutisches, diagnostisches und prognostisches verfahren für blasenkrebs
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
EP3242875B1 (de) 2015-01-09 2022-02-23 Genentech, Inc. 4,5-dihydroimidazol- derivate und ihre verwendung als histone demethylase (kdm2b) inhibitoren
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
CN107406414B (zh) 2015-01-09 2022-04-19 基因泰克公司 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
CN107438593B (zh) 2015-01-30 2020-10-30 基因泰克公司 治疗化合物及其用途
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
EP3294770B2 (de) 2015-05-12 2024-03-20 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für krebs
AU2016270625B2 (en) 2015-05-29 2022-10-06 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CA2988420A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
JP2018521019A (ja) 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
EP3310815A1 (de) 2015-06-17 2018-04-25 F. Hoffmann-La Roche AG Verfahren zur behandlung von lokal fortgeschrittenen oder metastatischen brustkrebsen unter verwendung von pd-1-achse-bindenden antagonisten und taxanen
US10287401B2 (en) 2015-07-01 2019-05-14 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN105001167B (zh) * 2015-07-16 2018-01-05 西安交通大学 1‑取代苯基‑3‑（4‑取代苯基氨基‑6‑喹唑啉基）脲类化合物及制备方法和用途
PL3341376T3 (pl) 2015-08-26 2021-08-02 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
US10017572B2 (en) 2015-09-25 2018-07-10 Genentech, Inc. Anti-tigit antibodies and methods of use
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
US11078528B2 (en) 2015-10-12 2021-08-03 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
EP3978500B1 (de) 2015-12-16 2023-11-22 Genentech, Inc. Verfahren zur herstellung tricyclischer-pi3k-inhibitor-verbindungen
JP6871255B2 (ja) 2015-12-30 2021-05-12 シントン・ベスローテン・フェンノートシャップ ゲフィチニブの結晶形ａを製造する方法
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
CN114395624A (zh) 2016-02-29 2022-04-26 基因泰克公司 用于癌症的治疗和诊断方法
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
EP3443120A2 (de) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Verfahren zur überwachung und behandlung von krebs
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
EP3464286B1 (de) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridinderivate zur behandlung von krebs
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20190054094A (ko) 2016-09-27 2019-05-21 세로 테라퓨틱스, 인코포레이티드 키메라 포식작용 수용체 분자
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
CN110418851A (zh) 2016-10-06 2019-11-05 基因泰克公司 癌症的治疗和诊断方法
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
CN110267678A (zh) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
MA47107B1 (fr) 2016-12-22 2021-11-30 Amgen Inc Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
EP3567030B1 (de) * 2016-12-30 2022-02-09 Medshine Discovery Inc. Chinazolinverbindung zur egfr-hemmung
ES2953595T3 (es) 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN111132972A (zh) 2017-06-22 2020-05-08 克拉德夫制药有限公司 人sting的小分子调节剂
EP3655034A1 (de) 2017-07-21 2020-05-27 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
MX2020000903A (es) 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
CN111386284A (zh) 2017-09-26 2020-07-07 森罗治疗公司 嵌合吞噬受体分子和使用方法
AU2018353984A1 (en) 2017-10-24 2020-05-07 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2019084395A1 (en) 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3085593A1 (en) 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
JP7450541B2 (ja) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換アミノピリミジン化合物及び使用方法
EP3759141A1 (de) 2018-02-26 2021-01-06 F. Hoffmann-La Roche AG Dosierung zur behandlung mit anti-tigit- und anti-pd-l1--antagonist-antikörpern
CA3093969A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
EP3774865A1 (de) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Zelluläre immunotherapiezusammensetzungen und ihre verwendungen
US20210087251A1 (en) 2018-03-28 2021-03-25 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3797173A2 (de) 2018-05-21 2021-03-31 Nanostring Technologies, Inc. Molekulare gensignaturen und verfahren zu deren verwendung
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
EP3807276A2 (de) 2018-06-12 2021-04-21 Amgen Inc. Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
EP3806887A4 (de) 2018-06-13 2022-04-06 California Institute of Technology Nanopartikel zur durchquerung der blut-hirn-schranke und behandlungsverfahren damit
CA3103017A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
EP3826988A4 (de) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC Verbindungen, derivate und analoga für krebs
CN112805267B (zh) 2018-09-03 2024-03-08 豪夫迈·罗氏有限公司 用作tead调节剂的甲酰胺和磺酰胺衍生物
WO2020055504A1 (en) * 2018-09-13 2020-03-19 University Of Southern California Novel inhibitors of guanosine monophosphate synthetase as therapeutic agents
MX2021003214A (es) 2018-09-19 2021-05-12 Genentech Inc Metodos terapeuticos y de diagnostico para el cancer de vejiga.
PL3857230T3 (pl) 2018-09-21 2023-10-16 F. Hoffmann-La Roche Ag Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas
KR20210079311A (ko) 2018-10-18 2021-06-29 제넨테크, 인크. 육종성 신장암에 대한 진단과 치료 방법
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (de) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen
AU2019401495A1 (en) 2018-12-20 2021-06-24 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
MX2021007158A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
AU2019403486A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
EP3897855B1 (de) 2018-12-20 2023-06-07 Amgen Inc. Kif18a-inhibitoren
EP3921443A1 (de) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnose- und therapieverfahren für krebs
US20220146495A1 (en) 2019-02-27 2022-05-12 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
CN113767100A (zh) 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
CN109796415B (zh) * 2019-03-29 2020-10-30 武汉德诺美生物医药股份有限公司 Egfr抑制剂及其应用
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
JP2022530674A (ja) 2019-05-03 2022-06-30 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体を用いたがんの処置方法
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
EP3972973A1 (de) 2019-05-21 2022-03-30 Amgen Inc. Festkörperformen
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
JP2022542319A (ja) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
JP2022542392A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
MX2022002738A (es) 2019-09-04 2022-06-27 Genentech Inc Agentes de union a cd8 y uso de los mismos.
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
EP4038097A1 (de) 2019-10-03 2022-08-10 Cero Therapeutics, Inc. Chimäre tim4-rezeptoren und verwendungen davon
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
PE20221278A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
EP4055017A1 (de) 2019-11-08 2022-09-14 Revolution Medicines, Inc. Bicyclische heteroarylverbindungen und verwendungen davon
CR20220207A (es) 2019-11-13 2022-06-06 Genentech Inc Compuestos terapéuticos y métodos de uso
EP4058465A1 (de) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4-antagonistenpeptide
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL293423A (en) 2019-12-13 2022-07-01 Genentech Inc Anti-ly6g6d antibodies and methods of use
TW202136276A (zh) 2019-12-20 2021-10-01 美商艾瑞斯卡公司 三環吡啶酮及嘧啶酮
KR20220124768A (ko) 2020-01-07 2022-09-14 레볼루션 메디슨즈, 인크. Shp2 억제제 투여 및 암 치료방법
AU2021212662A1 (en) 2020-01-27 2022-08-11 F. Hoffmann-La Roche Ag Methods for treatment of cancer with an anti-TIGIT antagonist antibody
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
EP4143345A1 (de) 2020-04-28 2023-03-08 Genentech, Inc. Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
CN111499583B (zh) * 2020-05-22 2022-02-15 沈阳工业大学 喹唑啉衍生物及其作为抗肿瘤药物的应用
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
JP2023531200A (ja) 2020-06-18 2023-07-21 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN116568824A (zh) 2020-08-03 2023-08-08 基因泰克公司 淋巴瘤的诊断和治疗方法
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
EP4196612A1 (de) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostische und therapeutische verfahren für krebs
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
EP4208261A1 (de) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Verwendung von sos1-inhibitoren zur behandlung von malignitäten mit shp2-mutationen
CN117683049A (zh) 2020-09-15 2024-03-12 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
EP4217071A1 (de) 2020-09-23 2023-08-02 Erasca, Inc. Tricyclische pyridone und pyrimidone
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
MX2023009379A (es) 2021-02-12 2023-10-10 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
CN117203223A (zh) 2021-02-26 2023-12-08 凯洛尼亚疗法有限公司 淋巴细胞靶向慢病毒载体
EP4334324A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2024517847A (ja) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
AU2022280025A1 (en) 2021-05-25 2023-12-07 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
EP4376874A1 (de) 2021-07-28 2024-06-05 Cero Therapeutics, Inc. Chimäre tim4-rezeptoren und verwendungen davon
EP4384522A1 (de) 2021-08-10 2024-06-19 Erasca, Inc. Selektive kras-hemmer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
US20230202984A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024085242A2 (en) 2022-10-21 2024-04-25 Kawasaki Institute Of Industrial Promotion Non-fouling or super stealth vesicle
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US398749A (en) * 1889-02-26 Harvey d
US3985742A (en) * 1971-12-01 1976-10-12 Merck & Co., Inc. Process for preparing 3-hydroxymethyl cephalosporins
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
JPS5620577A (en) * 1979-07-27 1981-02-26 Sankyo Co Ltd 4- n-alkylanilino quinazoline derivative and its preparation
US4510307A (en) * 1980-08-20 1985-04-09 Asahi Kasei Kogyo Kabushiki Kaisha 6-Quinazolinesulfonyl derivatives and process for preparation thereof
JPS57143266A (en) * 1981-02-27 1982-09-04 Shin Kobe Electric Mach Co Ltd Plate for lead acid battery
JPS57143296A (en) * 1981-02-28 1982-09-04 Matsushita Electric Works Ltd Switching unit
JPS5913765A (ja) * 1982-07-15 1984-01-24 Kyorin Pharmaceut Co Ltd ２−（４−キナゾリル）アミノ安息香酸誘導体
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
GB8424979D0 (en) * 1984-10-03 1984-11-07 Wyeth John & Brother Ltd Benzenesulphonamide derivatives
EP0572437B1 (de) * 1991-02-20 1995-04-26 Pfizer Inc. 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem

Also Published As

Publication number Publication date
CZ4393A3 (en) 1993-10-13
IL104479A0 (en) 1993-05-13
HU221622B1 (hu) 2002-12-28
NO930178L (no) 1993-07-21
SK281551B6 (sk) 2001-05-10
GR3018143T3 (en) 1996-02-29
HU9300094D0 (en) 1993-04-28
NO301541B1 (no) 1997-11-10
TW283146B (de) 1996-08-11
US5457105A (en) 1995-10-10
US5616582A (en) 1997-04-01
NZ245662A (en) 1995-09-26
UA34426C2 (uk) 2001-03-15
SK1693A3 (en) 1993-09-09
DK0566226T3 (da) 1996-03-18
FI930208A (fi) 1993-07-21
GB9300059D0 (en) 1993-03-03
HUT63153A (en) 1993-07-28
ATE130000T1 (de) 1995-11-15
CA2086968A1 (en) 1993-07-21
EP0566226B1 (de) 1995-11-08
AU3101093A (en) 1993-07-22
KR100229294B1 (ko) 1999-11-01
FI930208A0 (fi) 1993-01-19
HK36497A (en) 1997-04-04
ES2078798T3 (es) 1995-12-16
EP0566226A1 (de) 1993-10-20
DE69300754T2 (de) 1996-03-28
CA2086968C (en) 1998-06-23
RU2127263C1 (ru) 1999-03-10
AU661533B2 (en) 1995-07-27
FI111631B (fi) 2003-08-29
KR930016407A (ko) 1993-08-26
NO930178D0 (no) 1993-01-19
CZ282038B6 (cs) 1997-04-16
HU211311A9 (en) 1995-11-28
DE69300754D1 (de) 1995-12-14

Similar Documents

Publication Publication Date Title
CA2086968C (en) Quinazoline derivatives
US5475001A (en) Quinazoline derivatives
US5580870A (en) Quinazoline derivatives
US6015814A (en) Quinazoline derivative
CA2215732C (en) Quinazoline derivatives
US5880130A (en) 4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors
US5942514A (en) Quinazoline derivatives
US5952333A (en) Quinazoline derivative
US5932574A (en) Quinazoline derivatives
KR100489174B1 (ko) 4-아닐리노퀴나졸린유도체
JP2994165B2 (ja) キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
NZ243082A (en) 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
NZ286263A (en) 4 (substituted phenylamino) quinazoline derivatives, preparation and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired